An interventional study of Natural Cycle and Artificial Cycle in Infertility, Frozen Embryo Transfer and Preeclampsia and Eclampsia, sponsored by Indira IVF Hospital Pvt Ltd. Terminated at 1 site in India. Open to female participants aged 21 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-04-03.
Sponsored by Indira IVF Hospital Pvt Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this[ type of study: randomized controlled trial]is to compare Preeclampsia following Natural vs. Artificial Cycle in patients undergoing frozen embryo transfer.
The main question[s] it aims to answer is
The main objective is to compare the proportion of preeclampsia in women with a viable pregnancy with natural cycle protocol to artificial cycle protocol when practicing frozen embryo transfer. Participants recruited will be divided into two ARM(1513 per arm). ARM 1 will undergo the Natural Cycle procedure of Embryo transfer, and ARM 2 will undergo the Artificial Cycle procedure of Embryo transfer. The primary outcome will be the proportion of preeclampsia. The duration of the study is around 2 year.
The Research question(PICO) addressed is Does NC-FET decreases the incidence of preeclampsia in patients undergoing frozen embryo transfer as compared to AC-FET . The hypothesis taken is NC-FET will decrease the incidence of preeclampsia compared to AC-FET. The sample size is taken as 3026 (1513 per arm). The Primary Objective is to compare the proportion of preeclampsia in women with a viable pregnancy with natural cycle protocol to artificial cycle protocol when practicing frozen embryo transfer. The study outcome of the proportion of preeclampsia after 20 weeks of gestation or 6 weeks post-delivery. There are two arms-Arm 1 Active Comparator: Natural Cycle and Arm 2 control: Artificial Cycle FET. The Randomization is done through Random Allocation as per computer generated sequence. The Blinding/masking is done Open labeled. The Study Duration is from Feb 2023 to Jan 2025. Participation Duration is 10 months.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
This study's enrollment of 172 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Browse Infertility studies →Indira IVF Hospital Pvt Ltd is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this,hCG trigger and Luteal Phase Support is monitored for the natural frozen embryo cycle procedure of IVF.
Procedure: Natural Cycle
In this, endometrial preparation and Luteal Phase Support is monitored for the artificial frozen embryo cycle procedure of IVF.
Procedure: Artificial Cycle
The participant will be administered a S/C injection of 250mcg r-hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH \< 20 IU/L, the administration of r-hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone gel (8 %) twice daily starting 36 hrs after the trigger until ten weeks of gestation.
Estrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 21 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with transvaginal progesterone gel (8 %) twice daily starting from the day of embryo transfer until ten weeks of gestation. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping.
proportion of preeclampsia
The primary efficacy endpoint is the proportion of preeclampsia in women assigned to a natural cycle protocol compared to the proportion of preeclampsia in women assigned to an artificial cycle protocol.
Time frame: after the 20th week of gestation up to six weeks postpartum
Biochemical Pregnancy Rate
Pregnancies diagnosed only by β-human chorionic gonadotropin detection without a gestational sac visualized by vaginal ultrasound at the 6th gestational week.
Time frame: 6 weeks after Embryo Transfer
Implantation Rate
The number of gestational sacs observed by transvaginal ultrasound at the 6th gestational week per the number of embryos transferred.
Time frame: 4 weeks +2 weeks after ET
Clinical Pregnancy Rate
Detection of a foetal heartbeat on transvaginal ultrasound at the 6th gestational week per embryo transfer cycle.
Time frame: 4 weeks +2 weeks after ET
Ongoing Pregnancy Rate
Presence of gestational sacs with a heartbeat at the 12th gestational week per embryo transfer cycle.
Time frame: 12 weeks after embryo Transfer
Live Birth Rate
The number of deliveries that resulted in at least one live birth per 100 Embryo transferred cycle.
Time frame: 28 weeks(+12 weeks) after embryo transfer
Miscarriage Rate
Number of spontaneous pregnancy losses in which a gestational sac/s was previously observed (before 20th gestational weeks) per 100 clinical pregnancy.
Time frame: Within 20 weeks of gestation
Preterm birth
Preterm is defined as babies born alive before 37 weeks of pregnancy are completed
Time frame: < 37 weeks
Extreme preterm birth
Extreme Preterm is defined as babies born alive before 28 weeks of pregnancy
Time frame: 20-28 weeks
Fetal growth restriction
Fetal growth restriction (FGR) is most often defined as an estimated fetal weight less than the 10th percentile for gestational age by prenatal ultrasound evaluation
Time frame: 20-40 weeks of gestation
Fetal birthweight
Is defined as the weight of baby just after birth
Time frame: within 30 minutes of birth
Premature detachment of normally inserted placenta
It is defined as a premature separation of the placenta before delivery.
Time frame: 12 weeks of GA till labor
Maternal hypertension
It is defined as blood pressure more than 140/90 mm Hg detected first time after 20 weeks of gestation till 6 weeks of postpartum without proteinuria
Time frame: After 20 weeks of GA till 6 weeks postpartum
Eclampsia
Eclampsia is defined as the new onset of generalized tonic-clonic seizures in a woman with preeclampsia.
Time frame: After 20 weeks of GA till 6 weeks postpartum
HELLP Syndrome
It is defined as hemodialysis, elevated liver enzymes, and low platelet count
Time frame: After 20 weeks of GA till 6 weeks postpartum
Maternal mortality
Maternal death is defined as pregnancy or its management (excluding accidental or incidental causes) during pregnancy and childbirth or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy
Time frame: from start of pregnancy to 42 weeks of pregnancy
Fetal death
Fetal death refers to the spontaneous intrauterine death of a fetus after 20 weeks of GA before delivery
Time frame: 20 weeks of GA before delivery
Frequency of adverse events
An adverse event (AE) is any untoward medical occurrence in a patient.
Time frame: through study completion, an average of 1 year
Plan to share: Yes — IPD will be shared with other researchers after publication of primary results.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: After six months of publication of primary results statistical plan and ICF
Access criteria: IPD will be shared on request
Ran from Jul 2023 to primary completion in Mar 2024, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Indira IVF Hospital Pvt Ltd